曹氏益肾方辨治慢性肾衰竭68例

Clinical Efficacy of Cao's Kidney-Tonifying Prescription in Treatment of Chronic Renal Failure:A Report of 68 Cases

目的观察曹氏益肾方治疗慢性肾衰竭(chronic renal failure,CRF)的临床疗效。方法将128例CRF患者分为治疗组(68例)与对照组(60例)。治疗组服用曹氏益肾方,对照组服用肾衰宁胶囊和包醛氧淀粉胶囊,疗程12周。观察治疗前后两组患者血清肌酐(serum creatinine,SCr)、血尿素氮(blood urea nitrogen,BUN)、胱抑素C(cystatin-C,Cys C)、肾小球滤过率(glomerular filtration rate,GFR)的变化,观察并比较两组临床疗效和中医证候疗效。结果治疗组的临床疗效和中医证候疗效均显著优于对照组(P<0.05)。治疗后两组SCr、BUN和CysC水平均显著降低(P<0.01),而GFR水平显著升高(P<0.01);治疗组在降低SCr、BUN和CysC水平和升高GFR水平方面显著优于对照组(P<0.01)。两组在治疗期间均未出现药物不良反应。结论曹氏益肾方对非透析阶段CRF具有显著疗效及良好的安全性。

Objective To observe the clinical efficacy of Cao＇s Kidney-Tonifying Prescription （CKTP） in the treatment of chronic renal failure （CRF）. Methods A total of 128 non-dialysis patients with CRF were divided into treatment group （n=68） and control group （n= 60）. The treatment group received CKTP, while the control group received Shenshuaining Capsules and coated aldehyde oxystarch capsules. The course of treatment was 12 weeks for both groups. The changes in serum creatinine （SCr）, blood urea nitrogen （BUN）, cystatin C （Cys-C）, and glomerular filtration rate （GFR） were evaluated, and the clinical outcome and traditional Chinese medicine （TCM） outcome were compared between the two groups. Results The treatment group had significantly better clinical outcome and TCM syndrome outcome than the control group （P〈0.05）. After treatment, both groups showed significant decreases in SCr, BUN, and Cys-C （P〈0.01） and a significant increase in GFR （P〈0.01）, and the treatment group showed significantly more improvements in these pa rameters （P〈0.01）. No medication-related adverse events were found in either group during treatment. Conclusion CKTP is significantly effective and has good safety in non-dialysis patients with CRF.